Article
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients.
Scientific reports - 16 Jun 2017
Lee Mei-Hsuan, Huang Chung-Feng, Lai Hsueh-Chou, Lin Chun-Yen, Dai Chia-Yen, Liu Chun-Jen, Wang Jing-Houng, Huang Jee-Fu, Su Wen-Pang, Yang Hung-Chih, Kee Kwong-Ming, Yeh Ming-Lun, Chuang Po-Heng, Hsu Shih-Jer, Huang Ching-I, Kao Jung-Ta, Chen Chieh-Chang, Chen Sheng-Hung, Jeng Wen-Juei, Yang Hwai-I, Yuan Yong, Lu Sheng-Nan, Sheen I-Shyan, Liu Chen-Hua, Peng Cheng-Yuan, Kao Jia-Horng, Yu Ming-Lung, Chuang Wan-Long, Chen Chien-Jen
Abstract excerpt
This follow-up study enrolled chronic hepatitis C patients to evaluate the treatment efficacy and to identify post-treatment seromarkers associated with risk of hepatocellular carcinoma (HCC) among patients with a sustained virological response (SVR) or nonsustained virological response (NSVR). A total of 4639 patients who received pegylated interferon and ribavirin during 2004-2013 were followed until December...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.